Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 811 in systemic lupus erythematosus
NCT02291588Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2007
- Primary completion
- Mar 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing AMG 811 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Dec 2007; status: completed.
02
Drugs
amg 811
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02291588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291588.